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Malaria is a global health problem that causes significant
mortality and morbidity, with more than 1 million deaths
per year caused by P. falciparum. Most antimalarial drugs
face decreased efficacy due to the emergence of resistant
parasites. Therefore, the efforts to improve current treat-
ments are focused on the identification of new antimalarial
drugs displaying novel mechanisms of action.
To increase the probability of success to identify com-
pounds active against all relevant parasite drug targets,
phenotypic assays have been used to screen large com-
pound libraries against P. falciparum blood stages. At
GSK, 2M compounds were screened and 13500 con-
firmed hits (TCAMS-Tres Cantos Antimalarial Set)
were selected which inhibited P. falciparum growth with
IC50s below 2 μM.
In order to select chemotypes with a presumptive
novel mechanism of action, an early profiling is carried
out which involves several phases:
1. In the first phase, compounds are tested against a
wide panel of P. falciparum strains with well character-
ized genetic linkage to drug resistance to establish
which series had no cross-resistance with already known
antimalarial compounds. Panel includes laboratory
strains as well as clinical isolates.
2. In a second phase, compounds are tested using func-
tional assays to identify those molecules interfering with
parasite pathways that are targets of already known anti-
malarials (electron transport, folate and isoprenoid). Both
mitochondrial electron transport and pyrimidine bio-
synthesis inhibitors are identified using transgenic para-
sites overexpressing Saccharomyces cerevisiae DHODH.
Addition of proguanil to cultures restores cytochrome
bc1 blockage but not DHODH inhibition. Antifolates are
identified by supplementing the growth medium with
folic acid and, similarly, inhibitors of the isoprenoid bio-
synthesis pathway by adding geranyl geranyol or isopen-
tenyl pyrophosphate, which shifts the IC50 of inhibitors
of these pathways.
3. Finally compounds are subjected to hematin poly-
merization assays to establish the interference with this
essential pharmacological target of malaria parasites.
New scaffolds with novel modes of action can be
selected using these approaches avoiding the interference
with pathways which are known to develop resistance.
This strategy has already been succesful and our current
antimalarial pipeline is based on scaffolds displaying new
mechanisms of action. Chemoproteomics and chemical
genomics efforts are being used to decipher new MoA.
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